Treatment & Diagnostics

With our spin-out diagnostic partner Myconostica (winner of the North West BioNow Biomedical Project of the Year Award), we have developed clinically-validated and CE-marked detection of Aspergillus and Pneumocystis DNA from clinical samples. We have used the extracted DNA to detect antifungal resistance mutations directly, even in culture negative samples, and this is being clinically implemented for the first time for a fungus. We have identified novel anti-fungal drugs, one of which is in Phase 2.

The clinical spectrum of pulmonary aspergillosis.

The clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients, the critically ill patients and patients on steroids.